## MS Alkeon UCITS Fund

## Morgan Stanley

#### Factsheet 31-Oct-18

## A Sub-fund of Fundlogic Alternatives plc, an Irish UCITS Fund

## **Fund Objective and Investment Strategy**

Alkeon's investment philosophy is centered on performing deep fundamental analysis of individual company stocks and identifying growth cycles that are largely independent of the economic cycles. The portfolio's long investments emphasize positions in growth companies with improving fundamentals, strong balance sheets and free cash flows, and superior competitive positions. On the short side, Alkeon maintains an active alphaseeking stock specific portfolio by establishing short positions in low quality businesses facing long term challenges such as unstable and weak business models, deteriorating fundamentals, and declining profitability metrics. Core to the Alkeon approach is the concept that innovation often creates opportunities for growth, while at the same time it can destroy value - this leads to attractive long and short investment opportunities with the potential to create alpha on both sides of the portfolio.

Alkeon employs a bottom-up, fundamentally driven, research-intensive approach to investing, the core of which includes extensive analysis of business drivers and detailed modeling of projected earnings, executive-level understanding of industry competitive dynamics, market share shifts, profitability trends and growth rates, as well as extensive communications with industry leaders and executives globally. Alkeon has a mandate to pursue superior growth opportunities globally, including emerging markets.

#### **Investment Management**

Established in 2002, Alkeon Capital Management, LLC is a limited liability company registered as an investment advisor with the U.S. Securities and Exchange Commission. The company was founded by Panayotis "Takis" Sparaggis who has more than 20 years of experience in asset management.

Alkeon Capital Management, LLC manages approximately \$7.7 bn of assets under management through 4 different strategies. Alkeon has 51 employees and has offices in New York, Boston, San Francisco and Hong Kong.

#### **Fund Characteristics**

Inception Date	22-Jul-11
Total Assets (USD)	\$54m
Base Currency	USD
Domicile	Ireland
Passporting Status	Ireland, Italy, France, Germany, Luxembourg, Spain,
(registered in)	Switzerland and United Kingdom
Also permitted for sale	Singapore
to certain investors in	
Legal Structure	An Open-Ended Investment Company (OEIC)
Dealing Day	Weekly. Every Friday (except legal public holidays in the
	UK and Ireland and days on which stock markets in
	London are closed)
Subscription/	12 midday Irish time, 5 business days prior to the
Redemption notice	relevant dealing day
Settlement	Subscription: Dealing Day +3
	Redemption: Dealing Day +5
Currency Classes Available	USD / EUR / CHF / GBP
Investment Manager	Alkeon Capital Management, LLC.
investment manager	Morgan Stanley & Co International plc ("Morgan
Promoter & Distributor	Stanley")
Depositary	Northern Trust Fiduciary Services (Ireland) Ltd
Administrator	Northern Trust International Fund Administration
	Services (Ireland) Ltd

## Performance (1)



Ernst & Young

Sources: Morgan Stanley IED Sales & Trading, Northern Trust / MSCI World (MXWO Index) - Bloomberg. The above figures refer to the past. Past performance is not a reliable indicator of future results.

## Historical Monthly Returns (1)

		Jan	Feb	Mar	Apr	May	Jun	Jul <sup>(2)</sup>	Aug	Sept	Oct	Nov	Dec	YTD (2)
2011	Alkeon - Share I-USD	-	-	-	-	-	-	-1.46%	-4.12%	-3.75%	12.28%	-3.79%	-5.45%	-7.12%
	MSCI World Index	-	-	-	-	-	-	-3.16%	-7.26%	-8.85%	13.60%	-5.55%	-0.17%	-12.32%
2012	Alkeon - Share I-USD	5.79%	5.15%	3.68%	-0.75%	-3.99%	1.25%	0.93%	2.12%	-0.08%	-2.46%	0.82%	-0.34%	12.33%
	MSCI World Index	4.93%	4.66%	1.02%	-1.37%	-8.99%	4.93%	1.20%	2.29%	2.52%	-0.76%	1.07%	1.75%	13.18%
2013	Alkeon - Share I-USD	2.34%	-0.20%	0.85%	-1.06%	2.24%	-1.30%	4.29%	-2.34%	4.09%	1.79%	2.11%	1.70%	15.25%
	MSCI World Index	5.00%	-0.02%	2.10%	2.89%	-0.29%	-2.61%	5.19%	-2.33%	4.82%	3.83%	1.59%	2.01%	24.10%
2014	Alkeon - Share I-USD	-2.83%	3.62%	-3.59%	-2.21%	2.40%	1.55%	-1.33%	2.11%	-1.57%	2.62%	1.76%	-1.10%	1.10%
	MSCI World Index	-3.77%	4.81%	-0.09%	0.83%	1.63%	1.65%	-1.67%	2.00%	-2.88%	0.57%	1.84%	-1.71%	2.93%
2015	Alkeon - Share I-USD	-2.76%	5.80%	-0.97%	-0.15%	1.02%	-0.75%	1.28%	-5.02%	-6.12%	7.69%	-0.11%	-2.15%	-3.06%
	MSCI World Index	-1.88%	5.68%	-1.81%	2.16%	0.05%	-2.46%	1.73%	-6.81%	-3.86%	7.83%	-0.67%	-1.87%	-2.74%
2016	Alkeon - Share I-USD	-6.79%	-1.81%	2.87%	-1.57%	5.42%	-2.06%	4.30%	2.26%	0.50%	-0.82%	-2.26%	-2.48%	-3.04%
	MSCI World Index	-6.05%	-0.96%	6.52%	1.38%	0.23%	-1.28%	4.15%	-0.13%	0.36%	-2.01%	1.25%	2.29%	5.32%
2017	Alkeon - Share I-USD	4.74%	4.61%	1.67%	3.23%	6.34%	-1.66%	3.85%	2.77%	2.27%	3.96%	-0.52%	-1.38%	33.90%
	MSCI World Index	2.35%	2.58%	0.82%	1.33%	1.78%	0.25%	2.33%	-0.07%	2.08%	1.81%	1.99%	1.26%	20.11%
2018	Alkeon - Share I-USD	9.63%	-3.11%	-2.31%	-5.74%	3.44%	0.22%	-4.19%	4.80%	-0.85%	-10.14%			-9.29%
	MSCI World Index	5.22%	-4.30%	-2.48%	1.02%	0.31%	-0.17%	3.05%	1.04%	0.39%	-7.42%			-3.87%

Source: Morgan Stanley IED Sales & Trading, Northern Trust. The above figures refer to the past. Past performance is not a reliable indicator of future results. Performance is quoted net of fees and based on unaudited figures

## Investment Manager Commentary (3)

October offered negative results to global equities. Alkeon UCITS returned -10.14%. Portfolio performance was positive in Australia and negative in the U.S. Asia and Europe. Results were positive in utilities and materials and negative in all other sectors. Our short positions had positive performance during the month while our longs underperformed, and our market hedges contributed positively to performance during the month.

Last month market volatility increased markedly. On a gross basis, last month our long book was down approximately-10.5% (return on invested capital, excluding fx), while our short book including market hedges was up 7.7% (return on invested capital, excluding fx). Year-to-date, gross of management fees and other expenses, our long book has contributed approximately-0.7% to cumulative performance, our short-book excluding market hedges has contributed approximately-0.9% and market hedges

Last month's market correction has been mainly attributed to two factors: one, the increase in interest rates year-to-date, and two, fears about trade wars and tariffs. The first attributed driver was similar to the February market correction which proved to be ephemeral. In fact, higher interest rates generally affect stocks positively almost up to the 5% level on the ten year treasury yield – beyond that level the relationship between bonds and stocks inverts. On the trade war front, the news has been mixed, with some positive resolution (Canada, Mexico, South Korea, potentially Europe) offset with increased uncertainty on the China front. We believe a trade deal with China is a matter of when, not if.

Overall, we do not believelast month's correction was an indication of a structural market risk, such as a pending recession. On the contrary, we were comforted by the fact that bonds were actually down for the month (they tend to be up sharply in a structural correction), gold was up only modestly, the Japanese yen was actually down (it tends to go up in a structural correction, for example in 2008 the yen was up almost 19%) and high yield bonds corrected only modestly (HYG down -2.42% for the month of October).

Furthermore, last month we observed a significant disconnect between fundamentals and stock market reaction. We believe such moments of volatility and disconnect create compelling investment opportunities and believe overal

We remain equally excited about current long and short investment opportunities globally, as we continue to see se wide discrepancies between valuations and underlying fundamentals. In particular, we consider many high quality growt sectors, such as technology and healthcare, to be undervalued and attractive relative to the market. This is remarkable given these sectors' superior underlying fundamentals, stronger balance sheets and higher growth rates compared to the rest of the market, and even more so for the technology sector, where the secular growth outlook is meaningfully improving, in our view, coinciding with the sector entering a large-scale, broad-scope, highly impactful wave o technological innovation, similar to the internet wave of the 1990s. We believe this new era of Machine Learning, Artificial Intelligence, the Internet of Things and the rise of the Fully Connected Economy (an era that has been referred to as the

At month-end the forward-year weighted average EV/EBITDA (gross cash flow) multiple for our portfolio was approximately 9.2 times, a discount to the portfolio's 2018 weighted average consensus EBITDA growth rate of greater than 25%.

- dex information is included for illustration purposes only and is not intended to imply that the portfolio was similar to any index either in composition or element of risk. The Index performance is adjusted to match MS Alkeon UCITS Fund valuation period.
- 2. For 2011, Jul-11 and YTD performances are from 22-Jul-11
- 3. Information sourced from Alkeon Capital Management, LLC and mirrors the opinion and expectations of Alkeon only. It is not agreed with Morgan Stanley and may not mirror Morgan Stanley's views. FactSet provided forward-year EV/EBITDA for securities. EV/EBITDA may not be available for each security, and only EV/EBITDA numbers that Alkeon believes to be reasonable, between 0 and 200, were used in calculations. Long and short performance is based on the performance of single-name securities only, i.e., the performance of market hedges is excluded.

FOR PROFESSIONAL INVESTORS AND ELIGIBLE COUNTERPARTIES ONLY: Applications for shares in MS Alkeon UCITS Fund (the "Fund") should not be made without first consulting the current prospectus of FundLogic Alternatives plc ("the Company"), the Fund's current supplement, the Fund's KIID and the latest annual report and semi-annual report of the Company or such other documents available in your local jurisdiction. This informatic been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to the important information at the end of this document.

## **Morgan Stanley**

# MANAGEMENT MS Alkeon UCITS Fund

Factsheet 31-Oct-18

## Risk Metrics (4)

Exposure and Risk Summary							
	% of NAV						
Gross Exposure	195.5%						
Net Exposure (Delta adjusted)	65.6%						
Annualised Volatility (5)	13.0%						
Relative VaR (6)	0.48						


Position Summary	
	Number of Positions
No. of Long	57
No. of Short	46

	% of NAV
Top 5 Longs	23%
Top 5 Shorts	-7%

Source: Morgan Stanley IED Sales & Trading.


Source: Morgan Stanley IED Sales & Trading.

## Market Cap Analysis (Equities) (4)(7)




Source: Morgan Stanley IED Sales & Trading

## Sector Analysis (4)



Source: Morgan Stanley IED Sales & Trading.

## Geographic Analysis<sup>(4)</sup>



- 4. Month-end data used. For Options, where delta adjusted is not indicated, market premium is used as exposure
- 5. Indicative values as insufficient data points for statistical calculations. The volatility is computed as the standard deviation of the daily returns.
- 6. Var 99% 20 days computed against the MSCI WORLD as benchmark
- 7. Mega Cap (>= 20 Bn); Large Cap (>= 5 Bn, < 20 Bn); Mid Cap (>= 1 Bn, < 5 Bn); Small Cap (> 0, < 1 Bn).

FOR PROFESSIONAL INVESTORS AND ELIGIBLE COUNTERPARTIES ONLY: Applications for shares in MS Alkeon UCITS Fund (the "Fund") should not be made without first consulting the current prospectus of FundLogic Alternatives plc ("the Company"), the Fund's current supplement, the Fund's KIID and the latest annual report and semi-annual report of the Company or such other documents available in your local jurisdiction. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to the important information at the end of this document.

## MS Alkeon UCITS Fund

#### **Fund Share Class Details**

		Share Clas	s	Performance			l.	Fees <sup>(8)</sup>					
	Ccv	Min Inv	Launch Date	NAV	MTD	YTD	LTD	ISIN	BBG	SEDOL	Mgmt	Perf.	TER (10)
Class I	USD	1,000,000	22-Jul-11	1387.57	-10.14%	-9.29%	38.76%	IE00B66Q8211	FAMSAIU	B66Q821	2.0%	20%	2.25%
Class I	EUR	1,000,000	22-Jul-11	1299.03	-10.42%	-10.82%	29.90%	IE00B68CVQ25	FAMSAIE	B68CVQ2	2.0%	20%	2.25%
Class I	CHF	1,000,000	22-Jul-11	1290.06	-10.46%	-11.11%	29.01%	IE00B3Q2LM98	FAMSAIC	B3Q2LM9	2.0%	20%	2.25%
Class C (9)	EUR	1,000,000	02-Sep-11	1473.69	-10.31%	-10.11%	47.37%	IE00B5N8Q634	FAMSACE	B5N8Q63	1.0%	20%	1.25%
Class A	USD	10,000	25-Nov-11	1429.25	-10.00%	-9.00%	42.93%	IE00B6126197	FAMSAAU	B612619	2.5%	20%	2.75%
Class A	EUR	10,000	02-Mar-12	1221.31	-10.46%	-11.42%	22.13%	IE00B6874242	FAMSAAE	B687424	2.5%	20%	2.75%
Class A	CHF	10,000	10-Feb-12	1227.15	-10.50%	-11.51%	22.72%	IE00B6047G88	FAMSAAC	B6047G8	2.5%	20%	2.75%
Class A	GBP	10,000	15-Feb-13	1229.03	-10.31%	-10.42%	22.90%	IE00B3LDKT75	FAMSAAG	B3LDKT7	2.5%	20%	2.75%
Class P	USD	250,000	15-Feb-13	1294.97	-10.04%	-8.78%	29.50%	IE00B9492984	FAMSPUS	B949298	2.0%	20%	2.25%
Class P	EUR	250,000	28-Jun-13	1223.16	-10.42%	-11.36%	22.32%	IE00B948FX09	FAMSPEU	B948FX0	2.0%	20%	2.25%
Class P	GBP	250,000	19-Jul-13	1212.72	-10.22%	-10.03%	21.27%	IE00B945VM21	FAMSPBP	B945VM2	2.0%	20%	2.25%
Class H	EUR	5,000,000	16-Sep-18	889.23	-	-	-11.08%	IE00BG1VMW95	FAMSAHE	NA	1.5%	20%	1.75%
Class H	USD	5,000,000		To b	e Launche	d		IE00BG1VMV88			1.5%	20%	1.75%
Class H	GBP	5,000,000		To b	e Launche	d		IE00BG1VMY10			1.5%	20%	1.75%
Class H	CHF	5,000,000		To b	e Launche	d		IE00BG1VMX03			1.5%	20%	1.75%

Source: Morgan Stanley IED Sales & Trading. NAVs are computed by Northern Trust.

- 8. The Fund may impose an anti-dilution levy or adjustment on large subscriptions or redemptions.
- 9. Class C Shares (EUR/ CHF/ USD/ GBP) were initial investor share classes and therefore such Shares are no longer available for subscription until such time as may be determined by the Directors from time to time in their absolute discretion.
- 10. Total Expense Ratio includes Management Fees and Promoter fees. For share classes launched before 31-Jul-14, the TER is based on the expenses for the year ending 31-Jul-14. This figure may vary from year to year. The promoter fee was reduced from 0.40% to 0.25% effective November 1, 2017.

#### **Important Information**

This document has been prepared by Morgan Stanley & Co. International plc ("Morgan Stanley") as a marketing document to inform Professional Investors and Eligible Counterparties about certain matters concerning the MS Alkeon UCITS Fund (the "Fund"). Morgan Stanley is authorised and regulated by the Financial Conduct Authority. It has been prepared solely for informational purposes and does not seek to make any recommendation to buy or sell any particular security (including shares in the Fund) or to adopt any specific investment strategy. Any use of this document by a financial intermediary is restricted to clients for whom the information in this document and an investment in shares of the Fund has been considered to be suitable by that financial intermediary in view of that client's situation and purpose, subject always to the applicable regulatory standard. If such a client considers an investment in shares of the Fund, he / she should always ensure that he / she has satisfied herself / himself that she / he has been properly advised by that financial intermediary about the suitability of an investment.

This communication is only intended for and will be only distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations. Alkeon Capital Management ("Alkeon Capital") has been appointed as the investment manager to the Fund by the board of the Company. Alkeon Capital is an investment manager and is subject to the supervision of the Securities and Exchange Commission. All of the information contained in this document relating to Alkeon Capital (the "IM Information") is communicated by Morgan Stanley & Co International plc based on the information provided by Alkeon Capital. While the board of directors of FundLogic Alternatives plc (the "Company") has overall responsibility for the monitoring of the investment objective, policy and performance of the Fund, Morgan Stanley and its affiliates disclaim any and all liability relating to the IM Information, including, without limitation, any express or implied representations or warranties for statements or errors contained in, and omissions from, the IM Information.

This document does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. Applications for shares in the Fund should not be made without first consulting the current prospectus of the Company (the "Prospectus"), the Fund's supplement, the Fund's Key Investor Information Document ("KIID"), and the annual report and semi-annual report of the Company (together the "Offering Documents"), or other documents available in your local jurisdiction. The Offering Documents contain material information not contained herein. In particular, the Prospectus contains details relating to the terms of investment and information regarding investment risks and conflicts of interest. You should not rely solely on the information contained herein, but should carefully read the Offering Documents (including the KIID) before making any investment decision.

The material contained herein has not been based on a consideration of any individual client circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. Investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision. Except as otherwise indicated herein, the views and opinions expressed herein are those of Morgan Stanley. It is not a product of Morgan Stanley's research department and should not be regarded as a research recommendation. The information contained herein has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

No representation or warranty can be given with respect to the accuracy or completeness of the information, or with respect to the terms of any future offer of transactions conforming to the terms hereof. We do not undertake to update this information. Certain assumptions may have been made in the analysis that resulted in any information and returns / results detailed herein. No representation is made that any results / returns indicated would be achieved or that all assumptions in achieving these returns have been considered or stated. Changes to the assumptions may have a material impact on any results / returns detailed. Morgan Stanley and its affiliates disclaim any and all liability relating to this information, including without limitation any express or implied representations or warranties for statements contained in, and omissions from, this information.

Additional information concerning the Fund may be available upon request from Alkeon Capital.

This Fund may not be offered, sold or transferred in the United States to, or for the account or benefit of, any U.S. Person (as defined in Regulation S under the Securities Act of 1933). Shares in the Fund have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or the securities laws of any State in the United States, and may be subject to U.S. tax requirements. Shares in the Fund may not be offered, sold, transferred or delivered without compliance with all applicable securities laws and regulations.

Although this report has been prepared using sources, models and data that Morgan Stanley believes to be reasonably reliable, its accuracy, completeness or suitability cannot be guaranteed. Therefore, this information is supplied on an "AS IS" basis, and NO WARRANTY IS MADE AS TO ITS ACCURACY, COMPLETENESS, NON-INFRINGEMENT OF THIRD PARTY RIGHTS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

Alkeon Capital may from time to time, at its sole discretion and out of its own resources, decide to rebate to shareholders part or all of its investment management fee and/or performance fee. Any such rebates may be applied in cash. In addition to the information disclosed in the periodic reports of the Company, the Company may, from time to time, make available to investors, portfolio-related information in respect of the Fund. Any such information will be available to all investors in the Fund following a request from an investor. Any such information will only be provided on a historical basis and after the relevant dealing day to which the information relates.

#### Risk Warning

Past performance (including simulated data) is not a guarantee of future performance. Hypothetical performance results may have inherent limitations, some of which are described below. The value of the investments and the income from them can go down as well as up and an investor may not get back the amount invested. There can be no assurance that the Fund will achieve its investment objectives. As such, no representation is being made that any account will or is likely to achieve profits or losses similar to those shown. In fact, there are frequently differences between hypothetical performance results and the actual results subsequently achieved by any particular investment strategy. One of the limitations of hypothetical performance results is that they are generally prepared with the benefit of hindsight. The information presented does not constitute, and should not be construed as, investment advice or recommendations with respect to the securities or investments mentioned herein or to participate in any particular trading strategy.

Investments may be in a variety of currencies and therefore changes in rates of exchange between currencies may cause the value of investments to decrease or increase. Investments in derivative instruments carry certain inherent risks such as the risk of counterparty default, and before investing you should ensure you fully understand these risks. Use of leverage may also magnify losses as well as gains to the extent that leverage is employed. These investments are designed for investors who understand and are willing to accept these risks. Performance may be volatile, and an investor could lose all or a substantial portion of his or her investment.

Any estimates, projections or predictions (including in tabular form) given in this communication are intended to be forward-looking statements. Although Morgan Stanley believes that the expectations in such forward-looking statements are reasonable, it can give no assurance that any forward-looking statements will prove to be correct. The trademarks and service marks

# Alkeon Capital MANAGEMENT MS Alkeon UCITS Fund

## Morgan Stanley Factsheet 31-Oct-18

#### ADDITIONAL ALKEON DISCOLSURES:

The investment strategy of the Sub-Fund for which Alkeon Capital acts as Investment Manager involves substantial risks. No guarantee or representation is made that the investment program of the Sub-Fund will be successful.

The Investment Manager Information contained herein has been obtained by Alkeon Capital from sources deemed to be reliable, but is subject to unintentional errors, omissions and changes without notice, and is not warranted by Alkeon Capital as to its accuracy or completeness. It is the responsibility of the recipient to independently confirm the accuracy and completeness of the Investment Manager Information. Alkeon Capital does not assume any duty to update any Investment Manager Information in this document for subsequent changes of any kind.

Alkeon Capital has been appointed as the investment manager of the Fund by the board of the FundLogic Alternatives Plc (the "OEIC"). Morgan Stanley do not have a right to direct the investment of the Fund. The performance of the Fund will be dependent on the proper functioning of the internal management and systems of Alkeon Capital and the other service providers. The board of the OEIC will generally not have the opportunity to evaluate the specific investments made by Alkeon Capital before they are made.

Accordingly, no person should invest in the Fund unless willing to entrust all aspects of selection and management of the Fund's investments to Alkeon Capital. Morgan Stanley does not accept any liability for any losses caused by the actions or inaction of Alkeon Capital in connection with the performance of its management duties to the OEIC. The content hereof is intended for general information purposes only. The information contained herein is limited and is not intended to provide a representation of the merits or risks associated with an investment in any of the funds and accounts (the "Alkeon Funds") managed by Alkeon Capital.

The Fund is not benchmarked to any index and index performance has been shown for information purposes only. The MSCI World Index includes representation across 23 developed markets countries and is not administered by Morgan Stanley. The Fund's portfolio has exposure to equity securities and may consist of securities issued by companies in different countries with varying capitalizations and may have exposure to fixed income and non-equity investments, including having short positions in such securities. The underlying portfolio for the Fund is not as diversified as the securities (when aggregated) that comprise the MSCI World Index. As such ,the information contained herein is limited and is not a reliable indicator of the future results. Please refer to Fund's current supplement and the Fund's KIID for further details about its investment objectives and the investment policy.

#### **Selling Restrictions:**

The Fund may only be offered and distributed to investors in accordance with all relevant local laws and regulations. The distribution of this presentation and the offering or purchased of interests in the Fund may be restricted in certain countries. This communication is only intended for and will be only distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations. It is the responsibility of any persons in possession of this document and any persons wishing to purchase interests in the Fund to inform themselves of, and to observe, all applicable laws and regulations of any relevant country.

For Investors in France: The Offering Documents are also freely available upon request from BNP Paribas Securities Services, the centralising agent of the Fund in France: Les Grand Moulins de Pantin - 9, Rue de débarcadère 93500 Pantin (Heykel Khediri) - Tel: (+33 (0)1 57 43 83 09)

For investors in Italy: The Fund has been registered with the Commissione Nazionale per le Società e la Borsa (Consob) for the offer in Italy to Professional Investors only.

For investors in Spain: The Fund is registered with the Spanish Securities Market Commission (CNMV) under number 963 (www.cnmv.es), where the updated list of authorised distributors of the Company in Spain is available. The Spanish Distributors must provide each investor with a Spanish copy of the KIID and the latest published annual or semi-annual report prior to subscribing for Shares. In addition, a copy of the report on the planned types of marketing in Spain must be provided using the form published on the CNMV website. All mandatory official documentation shall be available through the Spanish Distributors, in hard copy or by electronic means at www.fundlogic.com.

For Investors in Hong Kong: This document is issued by Morgan Stanley Asia Limited ("Morgan Stanley Asia") and has not been reviewed by the Securities and Futures Commission of Hong Kong or any other regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. This document is only intended for and will only be distributed to persons that are professional investors as defined under the Hong Kong Securities and Futures Ordinance (Cap 571 of the Laws Hong Kong) and its subsidiary legislation as amended from time to time ("Professional Investors") and may not be circulated to the general public in Hong Kong. This Fund has not been authorised by the Securities and Futures Commission and may only be sold to Professional Investors, or in other circumstances which do not constitute an offer to the public for the purposes of the Securities and Futures Ordinance. Applications for shares in the Fund should not be made without first consulting the Offering Documents of the Fund.

This document has been prepared as information for Professional Investors in Hong Kong and it is not a recommendation to buy or sell any particular security or to adopt any investment strategy. Investors should exercise caution and seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision. Except as otherwise indicated herein, the views and opinions expressed herein are those of Morgan Stanley, and are based on matters as they exist as of the date of preparation and not as of any future date, and will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date hereof. No representation or warranty is given with respect to the accuracy or completeness of the information herein. This document is not a product of Morgan Stanley's research department and should not be regarded as a research recommendation.

For Investors in Singapore: This material is being disseminated in Singapore by Morgan Stanley Asia (Singapore) Pte., an entity regulated by the Monetary Authority of Singapore (the "MAS"). The Fund is not authorised or recognised by the MAS and shares in the Fund ("Shares") are not allowed to be offered to the Singapore retail public. This document does not relate to a collective investment scheme which is authorised under section 286 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") or recognised under section 287 of the SFA. This document is not a prospectus as defined in the SFA and has not been registered as a prospectus by the MAS and accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply.

In Singapore the offer of the Shares is made pursuant to the exemptions under Sections 304 and 305 of the SFA. Accordingly, the Shares may not be offered or sold, nor may the Shares be the subject of an invitation for subscription or purchase, nor may this material or any other document or material in connection with the offer or sale, or invitation for subscription or purchase of the Shares be circulated or distributed, whether directly or indirectly, to any person in Singapore other than under exemptions provided in the SFA for offers made (a) to an institutional investor (as defined in Section 4A of the SFA) pursuant to Section 304 of the SFA, (b) to a relevant person (as defined in Section 305(5) of the SFA), or any person pursuant to an offer referred to in Section 305(2) of the SFA, and in accordance with the conditions specified in Section 305 of the SFA or (c) otherwise pursuant to, and in accordance with, the conditions of any other applicable provision of the SFA.

Where the Shares are acquired by persons who are relevant persons specified in Section 305A of the SFA, namely:

- (a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
- (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, the shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within 6 months after that corporation or that trust has acquired the Shares pursuant to an offer made under Section 305 of the SFA except:
- (1) to an institutional investor or to a relevant person as defined in Section 305(5) of the SFA, or which arises from an offer referred to in Section 275(1A) of the SFA (in the case of that corporation) or which arises from an offer that is made on terms that such rights or interest in that trust are acquired at a consideration of not less than S\$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets (in the case of that trust);
- (2) where no consideration is or will be given for the transfer; or  $% \left( 1\right) =\left( 1\right) \left( 1\right)$
- (3) where the transfer is by operation of law;
- (4) as specified in Section 305A(5) of the SFA; or
- (5) as specified in Regulation 36 of the Securities and Futures (Offers of Investments) (Collective Investment Scheme) Regulations 2005 of Singapore.

For Investors in Switzerland: The representative and paying agent of FundLogic Alternatives plc, an Irish UCITS fund, in Switzerland is BNP PARIBAS Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich. The Prospectus, the supplement of the Fund and the KIIDs for Switzerland, the articles as well as the annual and semi-annual reports of FundLogic Alternatives plc may be obtained free of charge from the representative in Switzerland which is the place of jurisdiction of FundLogic Alternatives plc in Switzerland.

All information contained herein is proprietary and is protected under copyright [w] by Morgan Stanley 2018. All rights reserved.

FOR PROFESSIONAL INVESTORS AND ELIGIBLE COUNTERPARTIES ONLY: Applications for shares in MS Alkeon UCITS Fund (the "Fund") should not be made without first consulting the current prospectus of FundLogic Alternatives plc ("the Company"), the Fund's current supplement, the Fund's KIID and the latest annual report and semi-annual report of the Company or such other documents available in your local jurisdiction. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to the important information at the end of this document.